Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis I

ABSTRACT: Amisulpride, a known antipsychotic drug, was identified to target synovial fibroblasts activation in arthritis through novel identified targets.

ORGANISM(S): Mus musculus

PROVIDER: GSE211132 | GEO | 2023/04/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis II

Project description:Amisulpride, a known antipsychotic drug, was identified to target synovial fibroblasts activation in arthritis through novel identified targets.

2023-04-06 | GSE211137 | GEO

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis

Project description:Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis

| PRJNA953029 | ENA

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis I

Project description:Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis I

| PRJNA869070 | ENA

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis II

Project description:Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis II

| PRJNA869078 | ENA

Repurposing of Amisulpride, a known antipsychotic drug, to target synovial fibroblasts activation in arthritis.

Project description:Synovial Fibroblasts (SFs) are key pathogenic drivers in arthritis and their in vivo activation by TNF is sufficient to orchestrate full arthritic pathogenesis in animal models. TNF blockade has been efficacious for a large percentage of Rheumatoid Arthritis (RA) patients, although characterized by a plethora of side effects. Novel therapeutic discoveries remain however challenging, especially in optimizing drug safety, side effects, longer-term responses, costs and administration routes. Aiming to find new potent therapeutics, we applied the L1000CDS2 search engine, in order to identify compounds that could potentially reverse the pathogenic expression signature of arthritogenic SFs, derived from the human TNF transgenic mouse model (hTNFtg). We identified a neuroleptic drug, namely Amisulpride, which was validated to reduce SFs’ inflammatory potential while decreasing the clinical score of hTNFtg polyarthritis. Notably, we found that Amisulpride did not exert its biological activities through its known targets Dopamine receptors 2 and 3 and Serotonin Receptor 7, nor through TNFTNFRI binding inhibition. By applying a click chemistry approach, novel potential targets of Amisulpride were identified, which were further validated to repress hTNFtg SFs’ inflammatory potential in vitro (Ascc3 and Sec62), while phosphoproteomics analysis revealed important fibroblast activation pathways, such as adhesion, to be altered upon treatment. Our data support that Amisulpride could provide an additive beneficial effect to patients suffering from RA and comorbid dysthymia, as it may reduce SFs pathogenicity in parallel with its antidepressive activity. Importantly, Amisulpride may also serve as a “lead” compound for the development of novel, more potent therapeutics against chronic inflammatory diseases

2023-04-06 | PXD036283 | Pride

Repurposing the antipsychotic drug amisulpride for targeting synovial fibroblast activation in arthritis

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-04-06 | GSE229144 | GEO

Rsk2 controls synovial fibroblast hyperplasia and the course of arthritis.

Project description:To understand differences in the pathogenesis of synovial hyperplasia during TNF-induced arthritis, we compared the global gene expression of hTNFtg and hTNFtg;Rsk2-/y primary synovial fibroblasts.

2014-12-04 | GSE52992 | GEO

Repurposing of a known antipsychotic drug to target arthritogenic synovial fibroblasts

Project description:We applied quantitative mass spectrometry (MS)-based proteomics to investigate the phosphoproteome of hTNF-stimulated and Amisulpride-treated synovial fibroblasts (SFs), as part of a study aiming to find new potent orally-administered therapeutics to reverse the pathogenic expression signature of arthritogenic SFs. Phosphoproteomics analysis were done by DIA-based phosphoproteomic profiling of synovial fibroblasts. Samples consisted of hTNF-induced WT SFs. Three different time points (5’, 15’, 30’) of hTNF induction were used and compared to cells pretreated with Amisulpride for 1h before being stimulated at similar time points with hTNF (5’, 15’, 30’).

2023-04-11 | PXD035230 | Pride

RNA-seq analysis of freshly isolated synovial fibroblast subsets from patients with rheumatoid arthritis

Project description:Transcriptomics of distinct subpopulations of synovial fibroblasts from osteoarthritis and rheumatoid arthritis arthroplasty tissues.

2018-01-19 | GSE109448 | GEO

Microarray analysis of freshly isolated synovial fibroblast subsets in patients with rheumatoid arthritis or osteoarthritis

Project description:Transcriptomics of distinct subpopulations of synovial fibroblasts from osteoarthritis and rheumatoid arthritis arthroplasty tissues.

2018-01-17 | GSE107105 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data